Fluorothymidine F-18(Fluorothymidine F-18) - 在研适应症：急性淋巴细胞白血病，脑癌_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

+ [1]

靶点-

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [1]

在研适应症

急性淋巴细胞白血病脑癌

非在研适应症

肛门肿瘤脑转移瘤乳腺癌+ [12]

原研机构

National Cancer Institute

在研机构

The Children's Hospital Corp.

Advanced Innovative Partners Inc初创企业

非在研机构

National Institutes of HealthUNC Lineberger Comprehensive Cancer Center

National Cancer Institute

+ [4]

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C10H13FN2O4

InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N

CAS号287114-80-1

关联

49

项与 Fluorothymidine F-18 相关的临床试验

NCT03633955 / Recruiting临床1期IIT

Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

开始日期2023-01-19

申办/合作机构

University of Oklahoma

[+1]

NCT04309552 / Recruiting临床1期IIT

A Phase-I Trial for Simultaneous Imaging of Tumor Hypoxia and Proliferation in Patients With Treatment- Naïve High-Grade Glioma

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

开始日期2021-02-01

申办/合作机构

Weill Medical College of Cornell University

NCT04067115 / Active, not recruiting临床1/2期IIT

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Phase I was completed on 11/16/2022. Phase II is actively recruiting.

开始日期2021-01-05

申办/合作机构

Sarcoma Alliance for Research through Collaboration

[+3]

100 项与 Fluorothymidine F-18 相关的临床结果

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的转化医学

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的专利（医药）

登录后查看更多信息

31

项与 Fluorothymidine F-18 相关的文献（医药）

2023-11-01·Japanese Journal of Radiology

Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET

Article

作者: Oshima, Sonoko ; Sano, Kohei ; Nakamoto, Yuji ; Arakawa, Yoshiki ; Fushimi, Yasutaka ; Okuchi, Sachi ; Sakata, Akihiko ; Mineharu, Yohei ; Wang, Yang ; Hinoda, Takuya ; Nakajima, Satoshi ; Tanji, Masahiro ; Shimizu, Yoichi ; Yoshida, Kazumichi ; Ishimori, Takayoshi ; Otani, Sayo

AbstractPurposeThis study aimed to investigate the uptake characteristics of 18F-fluoromisonidazole (FMISO), in mutant-type isocitrate dehydrogenase (IDH-mutant, grade 3 and 4) and wild-type IDH (IDH-wildtype, grade 4) 2021 WHO classification adult-type diffuse gliomas.Materials and methodsPatients with grade 3 and 4 adult-type diffuse gliomas (n = 35) were included in this prospective study. After registering 18F-FMISO PET and MR images, standardized uptake value (SUV) and apparent diffusion coefficient (ADC) were evaluated in hyperintense areas on fluid-attenuated inversion recovery (FLAIR) imaging (HIA), and in contrast-enhanced tumors (CET) by manually placing 3D volumes of interest. Relative SUVmax (rSUVmax) and SUVmean (rSUVmean), 10th percentile of ADC (ADC10pct), mean ADC (ADCmean) were measured in HIA and CET, respectively.ResultsrSUVmean in HIA and rSUVmean in CET were significantly higher in IDH-wildtype than in IDH-mutant (P = 0.0496 and 0.03, respectively). The combination of FMISO rSUVmean in HIA and ADC10pct in CET, that of rSUVmax and ADC10pct in CET, that of rSUVmean in HIA and ADCmean in CET, were able to differentiate IDH-mutant from IDH-wildtype (AUC 0.80). When confined to astrocytic tumors except for oligodendroglioma, rSUVmax, rSUVmean in HIA and rSUVmean in CET were higher for IDH-wildtype than for IDH-mutant, but not significantly (P = 0.23, 0.13 and 0.14, respectively). The combination of FMISO rSUVmean in HIA and ADC10pct in CET was able to differentiate IDH-mutant (AUC 0.81).ConclusionPET using 18F-FMISO and ADC might provide a valuable tool for differentiating between IDH mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas.

2023-11-01·International journal of hematology

Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by ¹⁸F-FLT PET imaging.

Article

作者: Hosono, Naoko ; Kiyono, Yasushi ; Yamauchi, Takahiro ; Tsujikawa, Tetsuya ; Okazawa, Hidehiko ; Araie, Hiroaki

Cord blood is an important donor source for allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its unique composition and quality of hematopoietic cells. The proliferation site and potency of infused hematopoietic stem cells in humans may vary between stem cell sources. We investigated this possibility in a prospective, exploratory study to assess hematopoietic dynamics using the radiopharmaceutical 3'-deoxy-3'-¹⁸F-fluorothymidine (¹⁸F-FLT), a thymidine analog used in positron emission tomography imaging, before allo-HSCT and on days 50 and 180 after allo-HSCT. We evaluated 11 patients with hematological malignancies who underwent allo-HSCT [five with peripheral blood stem cell transplantation (PBSCT) and six with unrelated cord blood transplantation (UCBT)]. Before allo-HSCT, ¹⁸F-FLT uptake did not differ between the two groups. At day 50, ¹⁸F-FLT uptake in the spleen was significantly greater in the UCBT group than in the PBSCT group (p = 0.0043), with no difference in whole-body bone marrow. At day 180, the differences in spleen uptake had diminished, and there were no differences between groups in whole-body bone marrow or the spleen, except for the sternum. The persistence of splenic hematopoiesis after engraftment in the UCBT group may reflect the complex systemic homing and proliferation mechanisms of cord blood hematopoietic cells.

2023-02-01·Journal of Magnetic Resonance Imaging

Breast PET/MRI Hybrid Imaging and Targeted Tracers

Review

作者: Romeo, Valeria ; Pinker, Katja ; Helbich, Thomas H.

The recent introduction of hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) as a promising imaging modality for breast cancer assessment has prompted fervent research activity on its clinical applications. The current knowledge regarding the possible clinical applications of hybrid PET/MRI is constantly evolving, thanks to the development and clinical availability of hybrid scanners, the development of new PET tracers and the rise of artificial intelligence (AI) techniques. In this state‐of‐the‐art review on the use of hybrid breast PET/MRI, the most promising advanced MRI techniques (diffusion‐weighted imaging, dynamic contrast‐enhanced MRI, magnetic resonance spectroscopy, and chemical exchange saturation transfer) are discussed. Current and experimental PET tracers (18F‐FDG, 18F‐NaF, choline, 18F‐FES, 18F‐FES, 89Zr‐trastuzumab, choline derivatives, 18F‐FLT, and 68Ga‐FAPI‐46) are described in order to provide an overview on their molecular mechanisms of action and corresponding clinical applications. New perspectives represented by the use of radiomics and AI techniques are discussed. Furthermore, the current strengths and limitations of hybrid PET/MRI in the real world are highlighted.Evidence Level2Technical EfficacyStage 2

100 项与 Fluorothymidine F-18 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Fluorothymidine F-18	-	DB14930

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肛门肿瘤	临床2期	美国	National Institutes of Health	2012-10-01
宫颈癌	临床2期	美国	National Institutes of Health	2012-10-01
脑转移瘤	临床2期	美国	Angiochem, Inc.	2011-10-01
脑癌	临床2期	美国	The Children's Hospital Corp.	2010-10-01
乳腺癌	临床2期	-	Merck Sharp & Dohme Corp.	2010-04-08
喉肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
口腔肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
口咽肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
头颈部鳞状细胞癌	临床2期	美国	National Institutes of Health	2008-03-01
淋巴瘤	药物发现	美国	National Cancer Institute	2008-09-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (New Diagnosis of Brain Tumor)	廠鬱齋廠築簾淵願衊鏇(觸鹹鑰壓壓廠鬱膚製構) = 顧構糧網窪鹽願蓋齋憲淵願壓糧簾齋鬱夢壓窪 (選網顧構築鏇餘鏇積鹽, 範鑰憲鹽築醖糧膚蓋壓 ~ 積範築積壓窪憲憲繭築) 更多	-	2024-07-11
NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (Possible Recurrent Brain Tumor)	廠鬱齋廠築簾淵願衊鏇(觸鹹鑰壓壓廠鬱膚製構) = 淵鬱繭鏇廠簾齋餘顧壓淵願壓糧簾齋鬱夢壓窪 (選網顧構築鏇餘鏇積鹽, 衊蓋齋願齋獵顧醖窪顧 ~ 壓鏇餘製膚淵膚顧艱糧) 更多	-	2024-07-11
NCT03318497 (CTgov)	临床2期	胰腺腺癌	6	Computed Tomography+3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT	(積範獵糧選鹽淵衊構齋) = 積餘廠膚淵遞壓網壓積憲繭窪憲範鏇膚網衊網 (築蓋製製網膚憲築糧齋, 膚壓鑰膚糧糧顧鑰鏇憲 ~ 顧蓋選築選積餘廠觸選) 更多	-	2022-11-08
NCT01399658 (CTgov)	临床2期	阴道腺癌 \| 宫颈癌 \| 外阴肿瘤	93	Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine	積鹹淵願鬱齋構鏇鹹淵(築夢繭蓋蓋網憲鹹衊窪) = 齋淵淵獵憲壓鏇築衊膚窪選範鬱夢襯範壓膚鑰 (製鹽憲淵鬱憲鏇製範鹹, 鹽製壓顧範餘膚膚襯觸 ~ 築願製製繭鬱襯窪蓋網) 更多	-	2022-03-02
NCT00979810 (CTgov)	N/A	高级别胶质瘤	11	18F-FLT PET Scan	膚艱鹽衊窪糧壓範衊構(範網蓋選範壓網築築鑰) = 鹹膚衊鹽膚壓網鬱鹽糧廠鏇醖鹽構遞衊艱淵構 (餘齋積製糧鹹觸築膚襯, 夢襯鑰鏇鏇鏇繭網顧襯 ~ 鏇齋繭獵壓糧蓋遞壓糧) 更多	-	2020-12-17
ISC2019	N/A	缺血性卒中	-	F-18-fluorothymidine (Rats subjected to transient middle cerebral artery occlusion (MCAO))	選願憲醖鏇鹹蓋壓餘繭(鹹鏇獵範構襯築窪醖廠) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain 構餘範夢窪簾醖構簾獵 (願鏇鏇範襯膚鑰觸廠願 ) 更多	-	2019-02-01
NCT00721799 (CTgov)	临床2期	头颈部鳞状细胞癌 \| 喉肿瘤 \| 口咽肿瘤 \| 口腔肿瘤	33	18F-Fluorothymidine PET scan	簾壓顧鬱衊襯襯鹽鹹蓋(鬱窪鏇淵製齋鏇齋夢廠) = 簾夢淵簾鬱鬱衊網夢獵餘壓構構艱製壓壓獵選 (衊齋觸齋範襯範築繭餘, 鹽鹽艱築鹹獵遞鹽簾網 ~ 選夢齋衊廠艱製獵淵襯) 更多	-	2017-10-03
SNMMI2016	N/A	孤立性肺结节	-	18F-FLT18F-FDG (18F-FLT PET/CT)	網衊憲淵顧憲鹹網構觸(鏇簾顧選鏇築遞夢觸範) = 糧鹹夢鹽積網鏇憲繭鏇蓋觸選廠築鬱鹽選鹹獵 (齋膚糧廠顧鏇構壓壓繭 ) 更多	-	2016-05-24
NCT00572728 (ACRIN 6688, CTgov)	临床2期	局部晚期乳腺癌 \| 浸润性乳腺癌 \| 3型乳腺癌	90	PET+18F-FLT	願艱衊艱鏇觸夢憲糧簾(膚淵淵範糧鹽鹹鏇餘憲) = 廠繭繭鑰淵窪醖憲鑰夢餘範鹹廠構淵觸網夢築 (簾顧簾膚餘顧構壓壓憲, 夢襯積繭繭鑰觸鬱製願 ~ 鬱願餘夢糧壓繭築淵襯) 更多	-	2016-01-20
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	临床2期	乳腺癌新辅助	90	3'-Deoxy-3'-18F-Fluorothymidine	顧齋膚築獵遞遞艱願醖(壓築壓構顧顧選廠遞醖): P-Value = 0.05	-	2015-11-01
NCT00572728 (ACRIN 6688, Pubmed \| J Nucl Med)	临床2期	乳腺癌新辅助	90	Neoadjuvant Chemotherapy	顧齋膚築獵遞遞艱願醖(壓築壓構顧顧選廠遞醖): P-Value = 0.05	-	2015-11-01
JPRN-UMIN000009329 (ASCO2015)	临床2期	胃癌	20	<sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT) (18F-FLT PET/CT)	淵醖觸醖憲製衊壓齋艱(鑰蓋壓顧鬱鹹蓋鬱鑰膚) = 淵廠廠衊遞衊繭鑰餘鹹選襯夢蓋選鹹蓋構觸艱 (構窪鏇齋顧積糧簾積願 )	-	2015-05-20